226 related articles for article (PubMed ID: 23836358)
1. The Abbott RealTime High Risk HPV test is a clinically validated human papillomavirus assay for triage in the referral population and use in primary cervical cancer screening in women 30 years and older: a review of validation studies.
Poljak M; Oštrbenk A
Acta Dermatovenerol Alp Pannonica Adriat; 2013; 22(2):43-7. PubMed ID: 23836358
[TBL] [Abstract][Full Text] [Related]
2. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
3. Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study).
Monsonego J; Hudgens MG; Zerat L; Zerat JC; Syrjänen K; Smith JS
Gynecol Oncol; 2012 Apr; 125(1):175-80. PubMed ID: 22233689
[TBL] [Abstract][Full Text] [Related]
4. The Abbott RealTime High Risk HPV test: comparative evaluation of analytical specificity and clinical sensitivity for cervical carcinoma and CIN 3 lesions with the Hybrid Capture 2 HPV DNA test.
Poljak M; Kovanda A; Kocjan BJ; Seme K; Jancar N; Vrtacnik-Bokal E
Acta Dermatovenerol Alp Pannonica Adriat; 2009 Sep; 18(3):94-103. PubMed ID: 19784522
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the analytical and clinical performances of Abbott RealTime High Risk HPV, Hybrid Capture 2, and DNA Chip assays in gynecology patients.
Park S; Kang Y; Kim DG; Kim EC; Park SS; Seong MW
Diagn Microbiol Infect Dis; 2013 Aug; 76(4):432-6. PubMed ID: 23791386
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a multiplex real time PCR assay for the detection of human papillomavirus infections on self-collected cervicovaginal lavage samples.
Jentschke M; Soergel P; Hillemanns P
J Virol Methods; 2013 Oct; 193(1):131-4. PubMed ID: 23707925
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a new multiplex real-time polymerase chain reaction assay for the detection of human papillomavirus infections in a referral population.
Jentschke M; Soergel P; Lange V; Kocjan B; Doerk T; Luyten A; Petry KU; Poljak M; Hillemanns P
Int J Gynecol Cancer; 2012 Jul; 22(6):1050-6. PubMed ID: 22740006
[TBL] [Abstract][Full Text] [Related]
8. Performance of the Abbott RealTime high-risk HPV test in women with abnormal cervical cytology smears.
Cuzick J; Ambroisine L; Cadman L; Austin J; Ho L; Terry G; Liddle S; Dina R; McCarthy J; Buckley H; Bergeron C; Soutter WP; Lyons D; Szarewski A
J Med Virol; 2010 Jul; 82(7):1186-91. PubMed ID: 20513082
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the clinical performances of the AdvanSure HPV Screening Real-Time PCR, the Abbott Real-Time High-Risk HPV Test, and the Hybrid Capture High-Risk HPV DNA Test for Cervical Cancer Screening.
Chung HS; Hahm C; Lee M
J Virol Methods; 2014 Sep; 205():57-60. PubMed ID: 24814874
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Abbott RealTime High Risk HPV and Hybrid Capture 2 for the detection of high-risk HPV DNA in a referral population setting.
Venturoli S; Leo E; Nocera M; Barbieri D; Cricca M; Costa S; Santini D; Zerbini M
J Clin Virol; 2012 Feb; 53(2):121-4. PubMed ID: 22115872
[TBL] [Abstract][Full Text] [Related]
11. Concordance of Anyplex™ II HPV HR assays with reference HPV assays in cervical cancer screening: Systematic review.
Biazin H
J Virol Methods; 2022 Mar; 301():114435. PubMed ID: 34919974
[TBL] [Abstract][Full Text] [Related]
12. Clinical evaluation of human papillomavirus 16/18 oncoprotein test for cervical cancer screening and HPV positive women triage.
Yu L; Jiang M; Qu P; Wu Z; Sun P; Xi M; Qin Y; Liu X; Liao G; Lei X; Sun L; Zhang Y; Li Z; Chen W; Qiao YL
Int J Cancer; 2018 Aug; 143(4):813-822. PubMed ID: 29524206
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the clinical performance of the Abbott RealTime High-Risk HPV for carcinogenic HPV detection.
Halfon P; Benmoura D; Agostini A; Khiri H; Penaranda G; Martineau A; Blanc B
J Clin Virol; 2010 Aug; 48(4):246-50. PubMed ID: 20541966
[TBL] [Abstract][Full Text] [Related]
14. [Evaluation of a prototype real-time PCR assay for the separate detection of human papilloma virus genotypes 16 and 18 and other high risk human papillomavirus in cervical cancer screening].
Mateos ML; Chacón de Antonio J; Rodríguez-Domínguez M; Sanz I; Rubio MD
Enferm Infecc Microbiol Clin; 2011; 29(6):411-4. PubMed ID: 21435749
[TBL] [Abstract][Full Text] [Related]
15. [Role of HPV16/18/45 DNA testing of cervical specimens as a triage testing in cervical cancer screening].
Li J; Chen W; Kang LN; Chen F; Guo DP; Li BY; Qiao YL
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Jun; 35(3):254-9. PubMed ID: 23827061
[TBL] [Abstract][Full Text] [Related]
16. Comparison of hybrid capture 2 High-Risk HPV results in the low positive range with cobas® HPV Test results from the ATHENA study.
Rao A; Sandri MT; Sideri M; Young S; Sharma A; Behrens C
J Clin Virol; 2013 Sep; 58(1):161-7. PubMed ID: 23895930
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study.
Monsonego J; Hudgens MG; Zerat L; Zerat JC; Syrjänen K; Halfon P; Ruiz F; Smith JS
Int J Cancer; 2011 Aug; 129(3):691-701. PubMed ID: 20941740
[TBL] [Abstract][Full Text] [Related]
18. Comparison of clinical and analytical performance of the Abbott Realtime High Risk HPV test to the performance of hybrid capture 2 in population-based cervical cancer screening.
Poljak M; Ostrbenk A; Seme K; Ucakar V; Hillemanns P; Bokal EV; Jancar N; Klavs I
J Clin Microbiol; 2011 May; 49(5):1721-9. PubMed ID: 21430098
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Abbott RealTime High Risk HPV test in evaluation of atypical squamous cells of undetermined significance from an Asian screening population.
Wong OG; Lo CK; Szeto E; Cheung AN
J Clin Virol; 2011 Jun; 51(2):136-8. PubMed ID: 21530385
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel.
Polman NJ; Oštrbenk A; Xu L; Snijders PJF; Meijer CJLM; Poljak M; Heideman DAM; Arbyn M
J Clin Microbiol; 2017 Dec; 55(12):3544-3551. PubMed ID: 29021152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
